| Nov 5 |
Karyopharm Therapeutics GAAP EPS of -$0.26 beats by $0.03, revenue of $38.78M beats by $0.86M
|
| Nov 5 |
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
|
| Nov 4 |
Karyopharm Therapeutics Q3 2024 Earnings Preview
|
| Nov 1 |
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
|
| Oct 31 |
Karyopharm gains after changes to late-stage trial
|
| Oct 31 |
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
| Oct 31 |
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
|
| Oct 31 |
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
|
| Oct 30 |
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
|
| Oct 25 |
Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares
|
